MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
238.57
-1.49
-0.62%
After Hours: 237.00 -1.57 -0.66% 18:46 06/05 EDT
OPEN
241.95
PREV CLOSE
240.06
HIGH
241.99
LOW
236.11
VOLUME
678.00K
TURNOVER
--
52 WEEK HIGH
243.32
52 WEEK LOW
105.00
MARKET CAP
14.97B
P/E (TTM)
2244.31
1D
5D
1M
3M
1Y
5Y
1D
Jazz Pharmaceuticals To Present 21 Abstracts At SLEEP
Benzinga · 3d ago
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
PR Newswire · 3d ago
Is Ziihera’s HERIZON-GEA-01 Success Reframing the Oncology Investment Case for Jazz Pharmaceuticals (JAZZ)?
Simply Wall St · 3d ago
Jazz Pharma director Bruce C. Cozadd disposes of 6,000 shares for USD 1.41 million
PUBT · 3d ago
Jazz Pharmaceuticals Advances Cannabidiol Trial in Focal-Onset Seizures: What Investors Should Watch
TipRanks · 3d ago
Axsome marks ending of all patent disputes related to Sunosi
Seeking Alpha · 4d ago
Jazz Pharmaceuticals (JAZZ) Gets a Hold from Bernstein
TipRanks · 5d ago
Jessica Fye Reaffirms Buy on Jazz Pharmaceuticals, Citing Blockbuster Potential for Zanidatamab in First-Line HER2-Positive Gastric and Esophageal Cancers
TipRanks · 5d ago
More
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.